Clinical Trials Directory

Trials / Completed

CompletedNCT03596554

X-linked Hypophosphatemia and FGF21

X-linked Hypophosphatemia and Carbohydrate and Lipid Metabolism: a Role for FGF21?

Status
Completed
Phase
Study type
Observational
Enrollment
39 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
10 Years – 18 Years
Healthy volunteers

Summary

Fibroblast Growth Factor 23 and Fibroblast Growth Factor 21 are two endocrine Fibroblast Growth Factors, requiring Klotho as a co-factor to promote their systemic actions. Fibroblast Growth Factor 21 is involved in the regulation of glucid and lipid metabolism. Fibroblast Growth Factor 21 Knock Out mice display obesity and hyperglycemia. In investigators experience, patients with X-linked hypophosphatemia often present with early-onset over-weight that could be partly explained by decreased physical activity because of bone pains and deformations after puberty; however, patients usually display progressive over-weight earlier in life, when there is no limitation of physical activity yet. To the knowledge of investigators the association between Fibroblast Growth Factor 23, Fibroblast Growth Factor 21 and Klotho in patients with X-linked hypophosphatemia has never been evaluated. Thus, the main objective of this study is to evaluate the glucid and lipid metabolism in patients with X-linked hypophosphatemia, the main working hypothesis being that the genetic deregulation in the Fibroblast Growth Factor 23 axis in patients with X-linked hypophosphatemia induces modifications of Klotho levels (namely decreased levels) that in turn will deregulate the Fibroblast Growth Factor 21 axis (resistance to Fibroblast Growth Factor 21 because of decreased Klotho levels).

Conditions

Interventions

TypeNameDescription
OTHERDescriptive studyDescription of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).

Timeline

Start date
2019-01-11
Primary completion
2020-02-27
Completion
2020-02-27
First posted
2018-07-24
Last updated
2020-10-27

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03596554. Inclusion in this directory is not an endorsement.